Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market.
Employer coverage of GLP-1 weight-loss drugs fell from 72% in 2025 to 60% in 2026, and roughly 14% of surveyed employers have already dropped the medicines or plan to do so in 2027. That is the pressure squeezing the entire category.
Against that retreat, Eli Lilly (NYSE:LLY | LLY Price Prediction) just received something it can actually use in a payer meeting. On August 28, 2026, the FDA expanded Mounjaro’s label to reduce the risk of cardiovascular death, heart attack, and stroke in adults with type 2 diabetes at high cardiovascular risk. This is a diabetes label rather than a Zepbound obesity label, and the distinction matters for how much of the coverage rollback it can actually blunt.
What the Label Really Says
The underlying trial enrolled more than 13,000 patients and found 8% fewer major cardiovascular events with Mounjaro than with Lilly’s older Trulicity. An 8% relative reduction is real, but it is measured against another active GLP-1 rather than placebo, so the comparison tells payers that Mounjaro edges out an established therapy instead of proving that GLP-1s save lives from a standing start.
That nuance is why the label helps most where cardiovascular risk is already priced into premiums: diabetes case management, not general obesity coverage. Employers dropping GLP-1s are mostly cutting Zepbound-style weight-loss benefits, which this approval does not touch.
Still, the cardiovascular data gives Lilly a durable argument that treating comorbid diabetes prevents downstream hospital spending, and that argument travels.
Numbers Behind the Argument
Mounjaro revenue rose 91% in the second quarter to $9.94 billion, with U.S. growth of 45% and international growth of 172% following China’s addition of it to the national reimbursement list.
Total revenue reached $22.97 billion, and Lilly raised full-year guidance to $85.0 billion to $87.0 billion. CEO David Ricks said, “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance.”
Volume is driving the growth while pricing declines. U.S. price declined 9% excluding rebate adjustments, and CFO Lucas Montarce told investors, “expect that price will actually go down for sure … we are going to more than offset that with volume growth.”
Position on the Central Question
The label likely protects diabetes reimbursement more than it reopens obesity coverage. Approval does not compel a single insurer or employer to pay for anything, and pretending otherwise misreads how formularies work.
But it does give Lilly medical-necessity language for the diabetes patients most likely to be cut in a cost review, and, combined with the Medicare Bridge Program covering 20 million eligible Americans at $50 per month, it meaningfully narrows the exposure.
Shares trade at $1,174.61 and 32x forward earnings, with an analyst target of $1,315.04. The stock is down 6.44% in the past week, so the market has not yet priced the cardiovascular claim as a coverage shield. If Lilly can turn the label into contract language rather than press releases, that gap closes.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks.
